Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas

被引:97
作者
Kelaidi, C
Rollot, F
Park, S
Tulliez, M
Christoforov, B
Calmus, Y
Podevin, P
Bouscary, D
Sogni, P
Blanche, P
Dreyfus, F
机构
[1] Univ Paris 05, Hop Cochin, Dept Hematol, Assistance Publ Hop Paris, F-75014 Paris, France
[2] Univ Paris 05, Hop Cochin, Dept Internal Med 2, Assistance Publ Hop Paris, Paris, France
[3] Univ Paris 05, Hop Cochin, Dept Anat Pathol, Assistance Publ Hop Paris, Paris, France
[4] Univ Paris 05, Hop Cochin, Dept Internal Med 1, Assistance Publ Hop Paris, Paris, France
[5] Univ Paris 05, Hop Cochin, Dept Surg & Liver Transplantat, Assistance Publ Hop Paris, Paris, France
[6] Univ Paris 05, Hop Cochin, Dept Hepatogastroenterol, Assistance Publ Hop Paris, Paris, France
关键词
hepatitis C virus; marginal zone lymphoma; splenic lymphoma with villous lymphocytes; interferon; ribavirin; large granular lymphocyte leukemia;
D O I
10.1038/sj.leu.2403443
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A link between chronic hepatitis C virus (HCV) infection and low-grade B-cell lymphomas has been suggested by epidemiological studies. Marginal zone lymphomas (MZLs) including splenic lymphomas with villous lymphocytes are among the most frequently reported subgroups in the setting of chronic HCV infection. In this study, we examined the effect of antiviral treatment in eight patients with HCV-associated MZL. We found that five out of eight patients have responded to interferon alpha and ribavirin. In some cases, hematologic responses were correlated to virologic responses. In addition, we report a case of large granular lymphocyte leukemia occurring in association with MZL and HCV, and responding to interferon and ribavirin. We suggest that there is an etiologic link between HCV and antigen-driven lymphoproliferative disorders.
引用
收藏
页码:1711 / 1716
页数:6
相关论文
共 55 条
[1]   Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles [J].
Arcaini, L ;
Paulli, M ;
Boveri, E ;
Vallisa, D ;
Bernuzzi, P ;
Orlandi, E ;
Incardona, P ;
Brusamolino, E ;
Passamonti, F ;
Burcheri, S ;
Schena, C ;
Pascutto, C ;
Cavanna, L ;
Margrini, U ;
Lazzarino, M .
CANCER, 2004, 100 (01) :107-115
[2]   Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients [J].
Berger, F ;
Felman, P ;
Thieblemont, C ;
Pradier, T ;
Baseggio, L ;
Bryon, PA ;
Salles, G ;
Callet-Bauchu, E ;
Coiffier, B .
BLOOD, 2000, 95 (06) :1950-1956
[3]  
Callet-Bauchu E, 1999, GENE CHROMOSOME CANC, V26, P221, DOI 10.1002/(SICI)1098-2264(199911)26:3<221::AID-GCC6>3.0.CO
[4]  
2-9
[5]   Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia [J].
Casato, M ;
Mecucci, C ;
Agnello, V ;
Fiorilli, M ;
Knight, GB ;
Matteucci, C ;
Gao, L ;
Kay, J .
BLOOD, 2002, 99 (06) :2259-2261
[6]   Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection [J].
Casato, M ;
Agnello, V ;
Pucillo, LP ;
Knight, GB ;
Leoni, M ;
DelVecchio, S ;
Mazzilli, C ;
Antonelli, G ;
Bonomo, L .
BLOOD, 1997, 90 (10) :3865-3873
[7]   VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen [J].
Chan, CH ;
Hadlock, KG ;
Foung, SKH ;
Levy, S .
BLOOD, 2001, 97 (04) :1023-1026
[8]   No association between hepatitis C and B-cell lymphoma [J].
Collier, JD ;
Zanke, B ;
Moore, M ;
Kessler, G ;
Krajden, M ;
Shepherd, F ;
Heathcote, J .
HEPATOLOGY, 1999, 29 (04) :1259-1261
[9]  
De Re V, 2000, Blood, V96, P3578
[10]  
De Re V, 2000, INT J CANCER, V87, P211, DOI 10.1002/1097-0215(20000715)87:2&lt